High success rates for scleral lenses in graft-v-host-disease patients
These numbers are unsurprising to anyone who knows people with severe chronic GvHD (when they develop severe dry eye, among other things, following a bone marrow transplant for example), but nonetheless impressive:
- 97% of patients had improvement in quality of life
- 92% of patients continued to use sclerals (mean follow-up time was more than 1.5 years)
- Corneal damage, vision and quality of life were all assessed 2 months after starting and all improved
Bone Marrow Transplant. 2017 Jun;52(6):878-882. doi: 10.1038/bmt.2017.9. Epub 2017 Feb 20.Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC.Magro L1,2, Gauthier J1,2, Richet M3, Robin M4, Nguyen S5, Suarez F6, Dalle JH7, Fagot T8, Huynh A9, Rubio MT10, Oumadely R11, Vigouroux S8, Milpied N8, Delcampe A12, Yakoub-Agha I1,2,13.Author informationAbstractChronic GvHD-related keratoconjunctivitis sicca (cGvHD-related KCS) can significantly alter the quality of life of patients after allogeneic hematopoietic stem cell transplantation. The aim of this work was to assess the efficacy and tolerability of scleral lenses to treat severe cGvHD-related KCS. In this retrospective, multicenter study, we included 60 consecutive patients diagnosed with cGvHD-related KCS and fitted with scleral lenses. Patients were evaluated at baseline and at 2 months with the following tests: the Ocular Surface Disease Index (OSDI) to assess quality of life, the Oxford score to grade corneal damage and the logarithm of minimal angle of resolution (Log MAR) scale to determine visual acuity. We observed improvement in quality of life in 58 patients (97%). All parameters improved at 2 months. We observed significant differences at 2 months compared with baseline for the mean OSDI (86 versus 30, respectively, P<0.001), the mean Oxford score (3.2 versus 1.3, respectively, P<0.001) as well as visual acuity (Log MAR of 0.33 versus 0.10, respectively, P<0.001). Treatment with scleral lenses was discontinued in only 5 patients (8%) with a median follow-up of 20.5 months (range: 2-125 months). Scleral lenses were very efficient and well tolerated in patients with severe cGvHD-related KCS.